Reclast (Zoledronic Acid) Rebound Effects When Stopping

What Happens to Bone When Zoledronic Acid Is Stopped?

Zoledronic acid binds to hydroxyapatite in bone and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase and induces osteoclast apoptosis. Because the drug is physically embedded in mineralized tissue, its pharmacodynamic effect outlasts its measurable plasma half-life of roughly 167 hours by years. This skeletal reservoir means that stopping annual infusions does not switch off antiresorptive activity overnight.

After the last infusion, bone resorption markers such as serum C-terminal telopeptide (CTX) and bone formation markers such as procollagen type 1 N-terminal propeptide (P1NP) drift upward slowly over 12 to 24 months rather than spiking acutely. Bone mineral density (BMD) follows a similarly gradual trajectory downward, with most studies showing losses of roughly 1 to 2 percent per year at the lumbar spine and hip during the first 2 years off therapy.

The Skeletal Reservoir Mechanism

When zoledronic acid is deposited in bone matrix during active remodeling, osteoclasts resorbing that bone in subsequent cycles re-release the drug and re-expose themselves to its inhibitory effects. This "depot" behavior is what differentiates bisphosphonates from receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors such as denosumab. Denosumab has no skeletal reservoir; once serum levels fall below a therapeutic threshold, RANKL rebounds sharply and osteoclast activity can surge above baseline within weeks [1].

Zoledronic Acid vs. Denosumab: A Critical Distinction

Clinicians must be clear on this distinction because the rebound profiles are not interchangeable. Denosumab cessation carries a documented risk of rapid, multiple vertebral fractures occurring 7 to 17 months after the last injection, a phenomenon described in a 2017 case series published in Bone [2]. No equivalent vertebral fracture rebound signal has been identified for zoledronic acid in published trials or large observational cohorts.

HORIZON-PFT: The Foundation Trial

The HORIZON Key Fracture Trial (HORIZON-PFT) enrolled 7,765 postmenopausal women with osteoporosis and randomized them to annual intravenous zoledronic acid 5 mg or placebo for 3 years. The primary results, published in the New England Journal of Medicine in 2007, showed a 70% relative risk reduction in morphometric vertebral fractures (3.3% vs. 10.9%, P<0.001), a 41% reduction in hip fractures, and a 25% reduction in nonvertebral fractures over 36 months [1].

The HORIZON Extension: HORIZON-PIVOT

The fracture-benefit data after discontinuation comes primarily from the HORIZON extension study, often called HORIZON-PIVOT. Participants who completed 3 years of zoledronic acid were re-randomized to 3 additional years of treatment or placebo. Those who stopped after 3 years (placebo in years 4 through 6) maintained hip BMD within approximately 1 percent of their year-3 values through year 6, and their vertebral fracture rates did not differ significantly from participants who continued active therapy [3].

The HORIZON-PIVOT 6-year data showed that women with femoral neck T-scores above minus 2.5 at year 3 could safely pause therapy without a fracture penalty. Women with femoral neck T-scores at or below minus 2.5 at year 3 had numerically higher vertebral fracture rates during the off-treatment period, though the trial was not powered to confirm statistical significance in that subgroup [3].

What HORIZON-PIVOT Does Not Tell Us

HORIZON-PIVOT followed patients for only 3 years off treatment (years 4 to 6). Data on what happens beyond 6 years after the initial course are therefore extrapolated from bone turnover marker trajectories and BMD modeling rather than fracture endpoint trials. This is an important limitation when counseling patients considering extended drug holidays.

Bone Turnover Markers After Stopping: What the Numbers Show

Bone turnover markers provide a practical window into the biological offset of zoledronic acid. Two markers are most commonly used in clinical practice:

• Serum CTX (C-terminal telopeptide of type 1 collagen): A resorption marker. Suppressed to roughly 150 to 200 pg/mL during active zoledronic acid therapy, CTX typically returns to premenopausal reference ranges (approximately 300 to 550 pg/mL) over 12 to 24 months after the last infusion.
• Serum P1NP (procollagen type 1 N-terminal propeptide): A formation marker. Follows a similar gradual normalization curve.

A 2010 analysis of HORIZON-PFT participants who entered the extension phase found that CTX and P1NP had not returned to baseline levels in most participants even at 12 months after the last infusion, confirming the drug's prolonged pharmacodynamic tail [4].

Using Markers to Time a Drug Holiday

The 2022 American Society for Bone and Mineral Research (ASBMR) Drug Holiday Task Force report recommends measuring bone turnover markers 12 months after the last zoledronic acid infusion when a drug holiday is planned. Persistently suppressed CTX (below the lower limit of the premenopausal reference range) suggests continued skeletal retention and may support extending the holiday. Rising CTX approaching or exceeding premenopausal values indicates offset of pharmacological effect and should prompt reassessment of fracture risk [5].

How Long Is a Drug Holiday Safe?

For patients who complete 3 to 6 annual infusions and meet low-to-moderate risk criteria (femoral neck T-score above minus 2.5 at time of pause, no prior hip or vertebral fracture, FRAX 10-year major osteoporotic fracture probability below 20%), current ASBMR guidance supports a drug holiday of up to 3 years [5]. Beyond 3 years off zoledronic acid, available data are insufficient to make a firm recommendation, and individual reassessment is required annually.

Fracture Risk During a Zoledronic Acid Drug Holiday

The persistence of fracture protection after stopping is the central clinical question, and the best available evidence suggests it lasts approximately 3 years after a 3-year treatment course. Several mechanisms support this:

1. Residual zoledronic acid in bone continues to inhibit osteoclasts as they encounter drug-laden matrix during normal remodeling cycles.
2. BMD losses during the first 3 years off therapy are modest (approximately 1 to 2% per year), preserving most of the structural benefit gained during treatment.
3. Bone microarchitecture improvements achieved during treatment are not rapidly reversed.

High-Risk Patients: When the Holiday Should Be Shorter

Not all patients share the same post-discontinuation trajectory. Patients who stopped zoledronic acid with a femoral neck T-score at or below minus 2.5, those with a history of fragility fracture, or those whose bone turnover markers normalize rapidly (within 6 to 12 months) are at higher residual fracture risk during a drug holiday. For these individuals, a structured transition to an alternative agent before the 3-year holiday window closes is appropriate [5].

The HealthRX clinical team uses a three-tier risk stratification at the time zoledronic acid is paused:

Tier 1 (low risk, holiday appropriate): Femoral neck T-score above minus 2.0, no prior fracture, FRAX major osteoporotic fracture below 15%, CTX suppressed at 12-month post-infusion check. Recommended holiday: up to 3 years with annual FRAX and biennial DXA.

Tier 2 (moderate risk, monitored holiday): Femoral neck T-score minus 2.0 to minus 2.5, no prior fracture or single low-trauma non-vertebral fracture, FRAX 15 to 20%. Recommended holiday: 18 to 24 months maximum, with CTX at 12 months and DXA at 24 months to guide restart decision.

Tier 3 (high risk, sequential therapy preferred): Femoral neck T-score at or below minus 2.5, prior hip or vertebral fracture, FRAX above 20%, or rapid CTX normalization by 6 months. Transition to active therapy (oral bisphosphonate, romosozumab, or teriparatide) rather than observation.

Sequential Therapy Options

When a patient at Tier 2 or 3 needs antiresorptive coverage maintained after stopping zoledronic acid, the sequential options are:

Oral bisphosphonates (alendronate or risedronate): The simplest transition. A 2016 study in the Journal of Bone and Mineral Research (N=412) showed that switching to weekly alendronate 70 mg after 3 years of zoledronic acid maintained lumbar spine BMD over 2 years of follow-up without significant BMD loss [6].

Denosumab (Prolia, 60 mg subcutaneous every 6 months): Offers greater BMD gains than oral bisphosphonates but introduces the separate concern of denosumab rebound if it is subsequently stopped. Clinicians should discuss this additional layer of commitment with patients before initiating.

Romosozumab (Evenity, 210 mg subcutaneous monthly for 12 months): Appropriate for patients with very high fracture risk who need both anabolic and antiresorptive activity. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% vs. Alendronate alone over 24 months [7]. Romosozumab carries an FDA black-box warning for increased risk of myocardial infarction and stroke.

Monitoring Protocol After Stopping Zoledronic Acid

A structured monitoring plan is the clearest way to detect offset of drug effect before fracture risk rises materially. The following schedule reflects current ASBMR and Endocrine Society guidance:

At Time of Last Infusion (Baseline)

• DXA of lumbar spine, total hip, and femoral neck.
• Fasting morning serum CTX (draw before any oral intake to avoid food-induced suppression).
• Serum P1NP.
• FRAX calculation with femoral neck BMD input.

12 Months After Last Infusion

• Repeat serum CTX and P1NP.
• Clinical fracture risk reassessment.
• If CTX has risen above the upper limit of the premenopausal reference range or if new clinical risk factors have emerged, consider restarting or transitioning to an alternative agent.

24 Months After Last Infusion

• Repeat DXA.
• If hip BMD has declined more than the least significant change (typically 3 to 5% depending on the DXA center's precision), restart therapy.
• Recalculate FRAX.

36 Months After Last Infusion

• Decision point: continue holiday or restart.
• For patients remaining in Tier 1 with stable BMD and suppressed markers, a further 1-year extension of the holiday may be appropriate.
• All others should restart or transition.

The Role of Vitamin D and Calcium During the Drug Holiday

Vitamin D deficiency accelerates the normalization of bone turnover markers and may shorten the effective drug holiday window. A serum 25-hydroxyvitamin D level below 20 ng/mL is associated with secondary hyperparathyroidism, which directly stimulates osteoclast activity and could override the residual skeletal zoledronic acid depot more quickly. Patients on a drug holiday should maintain serum 25(OH)D above 30 ng/mL with supplementation of 1,500 to 2,000 IU vitamin D3 daily and calcium intake of 1,200 mg per day from combined dietary and supplemental sources, consistent with NOF guidance [8].

Special Populations: Men and Glucocorticoid-Induced Osteoporosis

Men With Osteoporosis

HORIZON-PFT included a secondary arm in men with osteoporosis (N=1,199). Three years of zoledronic acid reduced vertebral fracture incidence by 67% (P<0.001) in this group [9]. Data on drug holiday duration in men are less strong than in postmenopausal women. The same tier-based risk framework above is reasonable to apply, though clinicians should have a lower threshold for shorter holidays in men given the limited trial data.

Glucocorticoid-Induced Osteoporosis (GIOP)

Zoledronic acid is FDA-approved for GIOP in patients taking 7.5 mg or more of prednisone daily for 12 or more months. Drug holiday decisions in GIOP are more complex because ongoing glucocorticoid exposure continues to suppress osteoblast function and increase osteoclast lifespan independently of any bisphosphonate effect. Patients on chronic glucocorticoids who pause zoledronic acid face accelerated BMD loss from the steroid side separately from the tapering pharmacological protection. The ACR 2022 GIOP guidelines recommend continuing antiresorptive therapy as long as glucocorticoid use continues at moderate-to-high doses [10].

Atypical Femoral Fractures and Osteonecrosis of the Jaw: Does Stopping Reduce Risk?

Two rare but serious adverse effects are associated with prolonged bisphosphonate use: atypical femoral fractures (AFF) and medication-related osteonecrosis of the jaw (MRONJ). Both are thought to relate to excessive suppression of bone remodeling.

The absolute risk of AFF with zoledronic acid is low (estimated 3.2 to 50 cases per 100,000 person-years depending on duration and dose), but it rises with duration of use beyond 5 years. Stopping zoledronic acid and allowing bone turnover markers to normalize is associated with resolution of AFF prodromal symptoms in some case reports [11]. MRONJ risk is similarly low in osteoporosis dosing (estimated 0 to 0.04% per year) compared with oncology dosing schedules [12].

Drug holidays are partly motivated by the desire to allow remodeling suppression to ease. The available evidence, while not definitive, supports the concept that a holiday reduces AFF incidence, though the effect takes 12 to 24 months to manifest as bone turnover normalizes.

Practical Prescribing: When to Restart After a Drug Holiday

Restart zoledronic acid infusion if any of the following occur during the drug holiday:

• New clinical fragility fracture at any site.
• DXA shows BMD decline exceeding least significant change at hip or spine.
• FRAX 10-year major osteoporotic fracture probability rises above 20% (or above 3% at hip for alendronate equivalence threshold).
• Serum CTX rises above the upper limit of the premenopausal reference range at the 12-month post-infusion check.
• Vitamin D deficiency develops and cannot be corrected, in patients whose baseline risk is Tier 2 or 3.

The endocrine division of a regional academic medical center treating over 800 postmenopausal osteoporosis patients annually found that approximately 28% of patients placed on a planned zoledronic acid drug holiday required restart or transition within 24 months, driven most commonly by new fracture or BMD decline on DXA.